Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 1, 2012, Pages 60-69

  Graciano, Miguel L ^a   Mitchell, Kenneth D ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Immunohistochemistry; Kidney; Peptide hormones; Renal pathology; Renin angiotensin system

Indexed keywords

ALBUMIN; CELL NUCLEUS ANTIGEN; CYTOCHROME P450 1A1; IMATINIB; PEPTIDES AND PROTEINS; PROTEIN REN2; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; KIDNEY; KIDNEY CORTEX; MALE; MALIGNANT HYPERTENSION; MORPHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

EID: 83455196994     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00218.2011     Document Type: Article

References (70)

1. Baumann M, Leineweber K, Tewiele M, Wu K, Türk TR, Su S, Gössl M, Buck T, Wilde B, Heemann U, Kribben A, Witzke O. Imatinib ameliorates fibrosis in uraemic cardiac disease in BALB/c without improving cardiac function. Nephrol Dial Transplant 25: 1817-1824, 2010.
2. Boor P, Konieczny A, Villa L, Kunter U, van Roeyen CR, LaRochelle WJ, Smithson G, Arrol S, Ostendorf T, Floege J. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant 22: 1323-1331, 2007.
3. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20: 117-122, 1995.
4. Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 53: 129-132, 2009.
5. Chang Y, Uen YH, Chen CC, Lin SC, Tseng SY, Wang YH, Sheu JR, Hsieh CY. Platonin inhibited PDGF-BB-induced proliferation of rat vascular smooth muscle cells via JNK1/2-dependent signaling. Acta Pharmacologica Sinica In press.
6. Comper WD, Haraldsson B, Deen WM. Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 19: 427-432, 2008.
7. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF- and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114: 1308-1316, 2004.
8. Dobrian A, Wade SS, Prewitt RL. PDGF-A expression correlates with blood pressure and remodeling in 1K1C hypertensive rat arteries. Am J Physiol Heart Circ Physiol 276: H2159-H2167, 1999.
9. Eskildsen-Helmond YEG, Mulvany MJ. Pressure-induced activation of extracellular signal-related kinase 1/2 in small arteries. Hypertension 41: 891-897, 2003.
10. Farris AB, Adams CD, Brousaides N, Della Pelle PA, Collins AB, Moradi E, Smith RN, Grimm PC, Colvin RB. Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol 22: 176-186, 2011.
11. Franco M, Tapia E, Santamaria J, Zafra I, Garcia-Torres R, Gordon KL, Pons H, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Renal cortical vasoconstriction contributes to the development of saltsensitive hypertension after angiotensin II exposure. J Am Soc Nephrol 12: 2263-2271, 2001.
12. Graciano ML, Mouton CR, Patterson ME, Seth DM, Mullins JJ, Mitchell KD. Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible ANG IIdependent malignant hypertension. Am J Physiol Renal Physiol 292: F1858-F1866, 2007.
13. Graciano ML, Nishiyama A, Jackson K, Seth DM, Ortiz RM, Prieto- Carrasquero MC, Kobori H, Navar LG. Purinergic receptors contribute to early mesangial transformation and renal vessel hypertrophy during angiotensin II-induced hypertension. Am J Physiol Renal Physiol 294: F161-F169, 2008.
14. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a nonpressor mechanism. Hypertension 17: 626-635, 1991.
15. Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, Rush DN. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 14: 1662-1668, 2003.
16. Haraldsson B, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88: 451-487, 2008.
17. Heldin CH. Structural and functional studies on platelet-derived growth factor. Eur Mol Biol Organ 11: 4252-4259, 1992.
18. Howard CG, Mullins JJ, Mitchell KD. Transient induction of ANG II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to ANG II in Cyp1a1- Ren2 transgenic rats. Am J Med Sci 339: 543-548, 2010.
19. Hu Y, Bock G, Wick G, Xu Q. Activation of PDGF receptor á in vascular smooth muscle cells by mechanical stress. FASEB J 12: 1135-1142, 1998.
20. Iyoda M, Shibata T, Hirai Y, Kuno Y, Akizawa T. Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. J Am Soc Nephrol 22: 1486-1496, 2011.
21. Iyoda M, Shibata T, Kawaguchi M, Yamaoka T, Akizawa T. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with antiglomerular basement membrane glomerulonephritis. Kidney Int 75: 1060-1070, 2009.
22. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzi P, Floege J, Schwartz SM. Renal injury from angiotensin II-mediated hypertension. Hypertension 19: 464-474, 1992.
23. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, McGrath I, Kotelevtsev Y, Mullins JJ. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 276: 36727-36733, 2001.
24. Kantachuvesiri S, Haley CS, Fleming S, Kurian K, Whitworth CE, Wenham P, Kotelevtsev Y, Mullins JJ. Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats. Kidney Int 56: 414-420, 1999.
25. Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 44: 195-202, 2004.
26. Kim S, Zhan Y, Izumi Y, Yasumoto H, Yano M, Iwao H. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol 20: 2539-2545, 2000.
27. Ko SH, Cao W, Liu Z. Hypertension management and microvascular resistance in diabetes. Curr Hypertens Rep 12: 243-251, 2010.
28. Li C, Xu Q. Mechanical stress-initiated signal transductions in vascular smooth muscle cells. Cell Signal 12: 435-445, 2000.
29. Linseman DA, Benjamin CW, Jones DA. Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J Biol Chem 270: 12563-12568, 1995.
30. Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK, Schmitz C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D, Haller H. Hypertension-induced end-organ damage. A new transgenic approach to an old problem. Hypertension 33: 212-218, 1999.
31. Milani CJ, Kobori H, Mullins JJ, Mitchell KD. Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Med Sci 340: 389-394, 2010.
32. Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, Mullins JJ. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J Renin Angiotensin Aldosterone Syst 7: 74-86, 2006.
33. Mitchell KD, Mullins JJ. Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 289: F1210-F1216, 2005.
34. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expression by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 83: 1419-1424, 1989.
35. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 39: 316-322, 2002.
36. Negoro N, Kanayama Y, Haraguchi M, Umetani N, Nishimura M, Konishi Y, Iwai J, Okamura M, Inoue T, Takeda T. Blood pressure regulates platelet-derived growth factor A-chain gene expression in vascular smooth muscle cells in vivo. An autocrine mechanism promoting hypertensive vascular hypertrophy. J Clin Invest 95: 1140-1150, 1995.
37. Okamura M, Konishi Y, Nishimura M, Negoro N, Umetani N, Inoue T, Kanayama Y, Takeda T. Platelet-derived growth factor gene expression in kidneys of malignant hypertension. Blood Press Suppl 3: 17-21, 1992.
38. Opay AL, Mouton CR, Mullins JJ, Mitchell KD. Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 291: F612-F618, 2006.
39. Ortiz RM, Graciano ML, Seth D, Awayda MS, Navar LG. Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in ANG II-dependent hypertension. Am J Physiol Renal Physiol 293: F139-F147, 2007.
40. Ortiz RM, Mullins JJ, Mitchell KD. Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension in Cyp1a1-Ren2 transgenic rats. Am J Physiol Renal Physiol 293: F1584-F1591, 2007.
41. Ozawa Y, Kobori H, Suzaki Y, Navar LG. Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol 292: F330-F339, 2007.
42. Parker SB, Dobrian AD, Wade SS, Prewitt RL. AT1 receptor inhibition does not reduce arterial wall hypertrophy or PDGF-A expression in renal hypertension. Am J Physiol Heart Circ Physiol 278: H613-H622, 2000.
43. Parker SB, Wade SS, Prewitt RL. Pressure mediates angiotensin IIinduced arterial hypertrophy and PDGF-A expression. Hypertension 32: 452-458, 1998.
44. Patterson ME, Mouton CR, Mullins JJ, Mitchell KD. Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol 289: F754-F759, 2005.
45. Patterson ME, Mullins JJ, Mitchell KD. Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase metabolites in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol 294: F205-F211, 2008.
46. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 152: 159-166, 2010.
47. Ross R, Masuda J, Raines WW. Cellular interactions, growth factors, and smooth muscle proliferation in atherogenesis. Ann NY Acad Sci 598: 102-112, 1990.
48. Ruggenenti P, Cravedi P, Remuzzi G, Medscape. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 6: 319-330, 2010.
49. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 5: 73-79, 2003.
50. Sarzani R, Arnaldi G, Chobanian AV. Hypertension-induced changes of platelet-derived growth factor expression in rat aorta and heart. Hypertension 17: 888-895, 1991.
51. Sasahara M, Fries JWU, Raines EW, Grown AM, Westrum LE, Frosch MP, Bonthron DT, Ross R, Collins T. PDGF-b chains in neurons of the central nervous system, posterior pituitary, and in transgenic model. Cell 64: 217-227, 1991.
52. Savikko J, Rintala J, von Willebrand E. Early short-term plateletderived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation. Transplant Proc 38: 3231-3232, 2006.
53. Schellings MW, Baumann M, van Leeuwen RE, Duisters RF, Janssen SH, Schroen B, Peutz-Kootstra CJ, Heymans S, Pinto YM. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(m- Ren2)27 rats. Hypertension 47: 467-474, 2006.
54. Tanabe Y, Saito M, Ueno A, Nakamura M, Takeishi K, Nakayama K. Mechanical stretch augments PDGF receptor beta expression and protein tyrosine phosphorylation in pulmonary artery tissue and smooth muscle cells. Mol Cell Biochem 215: 103-113, 2000.
55. Ullrich A, Schlessinger J. Signal transduction by receptor with tyrosine kinase activity. Cell 61: 203-212, 1990.
56. Wang CT, Chin SY, Navar LG. Impairment of pressure-natriuresis and renal autoregulation in ANG II-infused hypertensive rats. Am J Physiol Renal Physiol 279: F319-F325, 2000.
57. Wang DH, Prewitt RL, Beebe SJ. Regulation of PDGF-A: a possible mechanism for angiotensin II-induced vascular growth. Am J Physiol Heart Circ Physiol 269: H356-H364, 1995.
58. Wang S, Wilkes MC, Leof EB, Hirschberg R. Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 298: F142-F149, 2010.
59. Weir M. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 29: 1803-1824, 2007.
60. Wenzel UO, Wolf G, Jacob I, Schwegler C, Qasqas A, Amman K, Helmchen U, Stahl RA. Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats. Nephrol Dial Transplant 18: 2005-2013, 2003.
61. Whitworth CE, Fleming S, Cumming AD, Morton JJ, Burns NJ, Williams BC, Mullins JJ. Spontaneous development of malignant phase hypertension in transgenic Ren-2 rats. Kidney Int 46: 1528-1532, 1994.
62. Whitworth CE, Fleming S, Kotelevtsev Y, Manson L, Brooker GA, Cumming AD, Mullins JJ. A genetic model of malignant phase hypertension in rats. Kidney Int 47: 529-535, 1995.
63. Williams DE, Prieto MC, Mullins JJ, Navar LG, Mitchell KD. AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren2 transgenic rats fed with a high salt diet. Am J Med Sci 339: 356-361, 2010.
64. Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 15, Suppl 6: 61-63, 2000.
65. Working Group of the International IgA Nephropathy Network, the Renal Pathology Society, Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76: 546-556, 2009.
66. Zanella MT, Ribeiro AB. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of the renoprotection studies. Clin Ther 24: 1019-1034, 2002.
67. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21: 1819-1834, 2010.
68. Zhan Y, Kim S, Kawano H, Iwao H. Enhancement of platelet-derived growth factor â-receptor tyrosine phosphorylation in hypertensive rats and its inhibition by calcium channel blocker. Hypertens Res 25: 295-301, 2002.
69. Zoja C, Corna D, Rottoli D, Zanchi C, Abbate M, Remuzzi G. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 70: 97-103, 2006.
70. Zou LX, Imig JD, Von Thun AM, Hymel A, Ono H, Navar LG. Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. Hypertension 28: 669-677, 1996.